Featured Research

from universities, journals, and other organizations

Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment

Date:
October 18, 2005
Source:
University of Pittsburgh Medical Center
Summary:
Treating breast cancer with MammoSite® resulted in a low risk of complications and was generally well tolerated, according to a University of Pittsburgh study. The study, presented at the 47th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Oct. 16 to 20, also evaluated cosmetic outcome of treatment with MammoSite and found that it was comparable to that of standard external beam radiation.

MammoSite, a type ofbreast brachytherapy (bray-kee-therapy), uses a single catheterinserted into the breast following lumpectomy, or surgical removal of atumor, to deliver a high dose of radiation. Once the catheter isinserted, a tiny balloon is inflated and loaded with radioactive seedsthat deliver prescribed levels of radiation to targeted tissuesurrounding the tumor site.

"MammoSite is a type of partialbreast irradiation that delivers radiation from the inside of thebreast directly to the tumor site where cancer cells are most likely toreside," said Sushil Beriwal, M.D., assistant professor at theUniversity of Pittsburgh School of Medicine and medical director ofradiation oncology at Magee-Womens Hospital of the University ofPittsburgh Medical Center (UPMC). "Ours is one of the largestsingle-institution studies to confirm that it does this safely and withan acceptable level of toxicity."

The study, which was designedto evaluate early outcomes of MammoSite brachytherapy, and was approvedby the FDA in 2002, evaluated toxicity in 100 patients treated betweenJune 2002 and October 2004 at the University of Pittsburgh CancerInstitute. The patients were followed between three and 30 monthssubsequent to treatment with an average follow-up time of one year.After treatment, patients were assessed at one week, one month and atthree-month intervals. While 14 percent of women had to have thecatheter removed because of various reasons, the majority of thepatients (86 percent) underwent treatment.

Post-treatmentcomplications included balloon rupture, infections, skin toxicity andseromas (persistence of the cavity where the lump was removed). Studyresults indicated that balloon rupture occurred in six patients (7percent) and wound infections occurred in 10 patients (12 percent). Nopatients had serious skin toxicities from treatment. A palpable seromawas observed in 34 of the patients (40 percent) and persisted beyondsix months of treatment in 22 patients (26 percent).

The studyalso evaluated cosmetic outcome of MammoSite treatment. Cosmeticoutcome refers to the physical similarity between the treated breastand the untreated breast. Forty-eight patients (56 percent) hadexcellent cosmetic outcomes; 32 patients (37 percent) had good cosmeticoutcomes; and seven patients (7 percent) had fair cosmetic outcomes.

"Ourfindings demonstrate that the toxicities associated with MammoSite weresimilar to results reported in the MammoSite brachytherapy registrytrial," said Dr. Beriwal. "The complications were acceptable and thecosmetic outcome was comparable to what we might see with standardexternal beam radiation." Dr. Beriwal added that follow-up studies willseek to assess the long-term effects as well as the efficacy of thetreatment compared with standard external beam radiation therapy andother types of breast brachytherapy.

###

MammoSite is manufactured by Cytyc Corporation based in Alpharetta, Ga.

Alsoinvolved in the study from the University of Pittsburgh's department ofradiation oncology were Anurag Agarwal, M.D.; Dwight E. Heron, M.D.;Jeffrey Falk, M.D., Ronald Johnson, M.D.; Robert Mogus, R.T.T.; HayeonKim, M.S.; Kristina Gerszten, M.D.; and Melvin Deutsch, M.D.


Story Source:

The above story is based on materials provided by University of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Medical Center. "Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment." ScienceDaily. ScienceDaily, 18 October 2005. <www.sciencedaily.com/releases/2005/10/051018075958.htm>.
University of Pittsburgh Medical Center. (2005, October 18). Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/10/051018075958.htm
University of Pittsburgh Medical Center. "Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment." ScienceDaily. www.sciencedaily.com/releases/2005/10/051018075958.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins